MNPR · Monopar Therapeutics
Market Cap
$764.78M
Shares
6.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$111.89
Open$112.85
Day$109.14–113.99
52W close$33.93–123.84
Avg vol 30d262K
Short int887K · 13.2% float · 3.5d
Short vol70%
DataAug 2024–Aug 2026
Filing10-Q · Aug 12
Raw chart and full-history price indicators begin at the captured split on Aug 13, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+51%
above
Price vs 50-day avg
+6%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
87%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+93%
trailing
YTD return
+71%
this year
Relative strength
+79%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $106 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.22% of float · ▼ -16.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+51%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
87%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $106 › 200d $74 — 50d above 200d
Institutional flow
Accumulating
+17% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.22% of float · ▼ -16.7% MoM · 3.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $34
Now $112 · 87%
Range high $124
vs 200-day avg +51%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MNPR
this stock
Monopar Therapeutics
|
$764.78M | +71.3% | — | — | 13.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 13, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MNPR | +3.9% | +3.3% | +92.7% | +3.3% | +71.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +3.4% | +0.3% | +79.3% | +0.3% | +58.5% |
Key facts
CIK
1645469
CUSIP
61023L207
13F (30d)
91 filings
90 filers
Visit website
Investor relations